glucagon vs glp-1 Effects of (blue arrows), (red arrows) and GIP (green GLP−1 Receptor Agonist Mechanisms GLP−1RAs

During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

Both eye conditions can cause blurry vision or sudden blindness

For additional information or questions about your treatment plan, visit your Alan Health Portal

However, skeletal deformities and growth defects were prominently seen in rat models with no conspicuous findings in humans (93)

But healing from birth is not something that should be rushed